查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954192

抗生素抗药性市场分析及预测（至2035年）：类型、产品、服务、技术、应用、最终用户、流程、组件、设备、解决方案

Antibiotic Resistance Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Component, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 399 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，抗生素抗药性市场规模将从2024年的109亿美元成长至218亿美元，年复合成长率约为8.2%。该市场涵盖了为应对细菌抗生素抗药性而开发的诊断、治疗方法和预防措施。推动该行业发展的动力源于对抗多重抗药性菌株和确保有效治疗方法的迫切需求。主要趋势包括对新型抗生素、快速诊断工具和全球抗生素管理计画的投资。不断提高的医疗保健意识和监管支持进一步推动了市场成长，为创新和合作应对这一重大公共卫生挑战提供了重要机会。

受新型治疗方法和诊断工具的迫切需求驱动，抗生素抗药性市场正经历强劲成长。就治疗领域而言，β-内酰胺类和β-内酰胺酶抑制剂类药物因其对抗药性菌的有效性而表现最佳。醣肽已成为第二大细分市场，为多重抗药性感染疾病提供了替代方案。诊断工具的重要性日益凸显，其中快速诊断发挥主导作用，能够快速识别抗药性病原体。次世代定序（NGS）技术紧随其后，提供全面的抗药性分析。旨在发现新型抗生素和抗抗药性药物的研发投入不断增加，进一步推动了市场发展。公私合营促进了创新，监管机构也支持加速核准流程。对抗生素管理计画（ASP）的日益重视凸显了永续使用抗生素的必要性，并为提供管理解决方案的公司创造了机会。随着抗生素抗药性威胁的日益加剧，策略伙伴关係和创新解决方案对于塑造未来至关重要。

市场区隔
类型 抗生素、抗病毒药物、抗霉菌药、抗寄生虫药
产品 药品、诊断试剂、疫苗
服务 咨询、检验和监测
科技 基因体学、蛋白质体学、生物资讯学、奈米技术
应用领域 人类医学、兽医学、农业
最终用户 医院、诊所、研究机构、製药公司
流程 药物研发、药物生产、品管
成分 原料药、辅料
医疗设备 实验室设备、照护现场设备
解决方案 感染控制，合理使用抗生素

抗生素抗药性市场正经历市场份额、定价和新产品发布方面的动态变化。主要产业参与者正透过创新应对日益严峻的抗药性挑战，从而形成具有竞争力的定价策略和尖端产品。频谱抗生素的研发和个人化医疗方法正日益受到关注。这一市场演变是由不断增长的医疗保健需求和对有效治疗方法的迫切需求所驱动的。竞争基准研究表明，该市场由少数几家大型製药企业主导，但新兴生物技术公司正在迅速崛起。监管因素，尤其是在北美和欧洲，正透过严格的核准流程和研发奖励影响市场动态。这些法规在确保安全性和有效性的同时，也促进了创新。策略联盟和併购是该市场的一个显着特征，有助于增强竞争优势。全球对有效抗生素解决方案的需求持续增长，为致力于对抗抗生素抗药性的相关人员提供了盈利的机会。

主要趋势和驱动因素：

抗菌药物抗药性市场正经历显着成长，这主要得益于人们对抗菌药物抗药性（AMR）作为全球健康威胁的认识不断提高。关键趋势包括新型抗生素和替代疗法的研发投入不断增加。各国政府和卫生组织正将抗菌药物抗药性应对计画列为优先事项，并加强合作以对抗抗药性。快速诊断技术的进步使得早期识别抗药性菌株成为可能，从而改善治疗效果并减少不合理使用抗生素。我们也看到，旨在加速药物发现和开发的公私合营激增。不断完善的法规结构正在简化新抗菌药物的核准流程，并促进创新。新兴市场感染疾病负担沉重，医疗基础设施不断完善，这些市场蕴藏着许多机会。专注于开发价格合理且易于获取的解决方案的公司，将占据有利地位，从而获得可观的市场份额。此外，人工智慧在药物发现过程中的应用可望透过提高新抗生素开发的效率和效果，进一步改变市场格局。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 抗生素
    • 抗病毒药物
    • 抗真菌药物
    • 抗寄生虫药物
    • 其他的
  • 市场规模及预测：依产品划分
    • 製药
    • 诊断
    • 疫苗
    • 其他的
  • 市场规模及预测：依服务划分
    • 咨询
    • 检查室检测
    • 监测
    • 其他的
  • 市场规模及预测：依技术划分
    • 基因组学
    • 蛋白质体学
    • 生物资讯学
    • 奈米科技
    • 其他的
  • 市场规模及预测：依应用领域划分
    • 人类药物
    • 动物医药
    • 农业
    • 其他的
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 製药公司
    • 其他的
  • 市场规模及预测：依製程划分
    • 药物研发
    • 製药生产
    • 品管
    • 其他的
  • 市场规模及预测：依组件划分
    • 原料药
    • 添加剂
    • 其他的
  • 市场规模及预测：依设备划分
    • 实验室设备
    • 照护现场设备
    • 其他的
  • 市场规模及预测：按解决方案划分
    • 感染控制
    • 合理使用抗生素
    • 其他的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Melinta Therapeutics
  • Nabriva Therapeutics
  • Paratek Pharmaceuticals
  • Iterum Therapeutics
  • Motif Bio
  • Spero Therapeutics
  • Entasis Therapeutics
  • Achaogen
  • Venatorx Pharmaceuticals
  • Qpex Biopharma
  • Forge Therapeutics
  • Bugworks Research
  • Nosopharm
  • Bioversys
  • Debiopharm
  • Antabio
  • Acurx Pharmaceuticals
  • Aridis Pharmaceuticals
  • Macrolide Pharmaceuticals
  • Allecra Therapeutics

第九章：关于我们

简介目录
Product Code: GIS25770

Antibiotic Resistance Market is anticipated to expand from $10.9 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 8.2%. The Antibiotic Resistance Market encompasses the development and distribution of diagnostics, therapeutics, and preventive measures addressing bacterial resistance to antibiotics. This sector is driven by the urgent need to combat multidrug-resistant strains and ensure effective treatments. Key trends include investments in novel antibiotics, rapid diagnostic tools, and global stewardship programs. Rising healthcare awareness and regulatory support further propel market growth, offering substantial opportunities for innovation and collaboration in addressing this critical public health challenge.

The Antibiotic Resistance Market is experiencing robust growth, fueled by the urgent need for novel treatments and diagnostic tools. Within the therapeutic segment, the beta-lactam and beta-lactamase inhibitors sub-segment is the top-performing, driven by its effectiveness against resistant strains. Glycopeptides emerge as the second highest-performing sub-segment, offering alternatives for multi-drug resistant infections. Diagnostic tools are gaining prominence, with rapid diagnostics leading the charge, enabling timely identification of resistant pathogens. Next-generation sequencing (NGS) technologies follow closely, providing comprehensive resistance profiling. The market is further bolstered by increasing investments in research and development, aimed at discovering new antibiotics and resistance breakers. Public-private partnerships are enhancing innovation, while regulatory support accelerates approval processes. The growing emphasis on antimicrobial stewardship programs underscores the need for sustainable antibiotic use, creating opportunities for companies offering stewardship solutions. As the threat of antibiotic resistance intensifies, strategic collaborations and innovative solutions will be pivotal in shaping the market's future trajectory.

Market Segmentation
TypeAntibiotics, Antivirals, Antifungals, Antiparasitics
ProductDrugs, Diagnostics, Vaccines
ServicesConsulting, Laboratory Testing, Surveillance
TechnologyGenomics, Proteomics, Bioinformatics, Nanotechnology
ApplicationHuman Medicine, Veterinary Medicine, Agriculture
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies
ProcessDrug Development, Drug Manufacturing, Quality Control
ComponentActive Pharmaceutical Ingredients, Excipients
DeviceLaboratory Instruments, Point-of-Care Devices
SolutionsInfection Control, Antimicrobial Stewardship

The Antibiotic Resistance Market is witnessing a dynamic shift in market share, pricing, and new product launches. Key industry players are innovating to address the growing resistance challenges, resulting in competitive pricing strategies and cutting-edge product offerings. The focus is on developing broad-spectrum antibiotics and personalized medicine approaches. This market evolution is driven by increasing healthcare demands and a critical need for effective treatments. Competition benchmarking reveals a landscape dominated by a few major pharmaceutical companies, with emerging biotech firms gaining traction. Regulatory influences, particularly in North America and Europe, are shaping market dynamics by enforcing stringent approval processes and incentivizing research. These regulations drive innovation while ensuring safety and efficacy. The market is characterized by strategic partnerships and mergers, enhancing competitive positioning. The global demand for effective antibiotic solutions continues to rise, presenting lucrative opportunities for stakeholders committed to combating antibiotic resistance.

Geographical Overview:

The antibiotic resistance market is witnessing varied growth dynamics across regions, with distinct opportunities emerging. North America leads the market, driven by advanced healthcare infrastructure and significant investments in research to combat antibiotic resistance. The region's proactive measures and government initiatives are crucial in addressing this escalating concern. Europe follows with substantial investments in antibiotic stewardship programs and research initiatives. The European Union's stringent regulations and collaborative efforts among member states are fostering a robust market environment. Asia Pacific is a rapidly growing market, propelled by increasing awareness and rising healthcare expenditures. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure and research to tackle antibiotic resistance. Latin America and the Middle East & Africa are emerging as promising regions. In Latin America, countries like Brazil and Mexico are enhancing their healthcare systems, while in the Middle East & Africa, growing investments in healthcare are paving the way for market expansion.

Global tariffs and geopolitical tensions are significantly influencing the Antibiotic Resistance Market. In Japan and South Korea, strategic investments in biotech innovation and domestic pharmaceutical production are intensifying to mitigate import dependencies. China, facing international scrutiny and trade barriers, is bolstering its internal capabilities through robust R&D initiatives. Taiwan, while a pivotal player in pharmaceutical manufacturing, navigates geopolitical challenges by enhancing regional collaborations. The parent market is witnessing substantial growth driven by rising antimicrobial resistance awareness and government initiatives. By 2035, market evolution will hinge on technological advancements and cross-border partnerships. Concurrently, Middle East conflicts exert pressures on global supply chains and energy prices, indirectly affecting production costs and logistics in the pharmaceutical sector, thereby shaping strategic responses in these East Asian economies.

Key Trends and Drivers:

The antibiotic resistance market is experiencing pivotal growth driven by heightened awareness of antimicrobial resistance (AMR) as a global health threat. Key trends include increased research and development investments in novel antibiotics and alternative therapies. Governments and health organizations are prioritizing AMR action plans, fostering collaborations to combat resistance. Advancements in rapid diagnostic technologies are enabling quicker identification of resistant strains, thereby improving treatment outcomes and reducing inappropriate antibiotic use. The market is also witnessing a surge in public-private partnerships aimed at accelerating drug discovery and development. Regulatory frameworks are evolving to incentivize innovation and streamline approval processes for new antimicrobial agents. Opportunities abound in emerging markets where the burden of infectious diseases is high and healthcare infrastructure is expanding. Companies that focus on developing affordable and accessible solutions are well-positioned to capture significant market share. Additionally, the integration of artificial intelligence in drug discovery processes is expected to further revolutionize the market by enhancing the efficiency and effectiveness of new antibiotic development.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Device
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antibiotics
    • 4.1.2 Antivirals
    • 4.1.3 Antifungals
    • 4.1.4 Antiparasitics
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Diagnostics
    • 4.2.3 Vaccines
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Laboratory Testing
    • 4.3.3 Surveillance
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Bioinformatics
    • 4.4.4 Nanotechnology
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Human Medicine
    • 4.5.2 Veterinary Medicine
    • 4.5.3 Agriculture
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Drug Development
    • 4.7.2 Drug Manufacturing
    • 4.7.3 Quality Control
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Active Pharmaceutical Ingredients
    • 4.8.2 Excipients
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Laboratory Instruments
    • 4.9.2 Point-of-Care Devices
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Infection Control
    • 4.10.2 Antimicrobial Stewardship
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Device
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Device
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Device
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Device
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Device
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Device
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Device
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Device
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Device
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Device
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Device
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Device
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Device
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Device
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Device
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Device
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Device
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Device
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Device
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Device
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Device
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Device
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Device
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Device
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Melinta Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Nabriva Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Paratek Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Iterum Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Motif Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Spero Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Entasis Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Achaogen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Venatorx Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Qpex Biopharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Forge Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bugworks Research
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Nosopharm
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bioversys
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Debiopharm
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Antabio
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Acurx Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Aridis Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Macrolide Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Allecra Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us